Preface
With the rapid advancement of the biopharmaceutical industry, the demand for the development of high-concentration protein formulations (HCPF, >100 mg/ml) continues to grow. High-concentration protein formulations play a pivotal role in the treatment of major diseases such as autoimmune disorders and oncology indications. Compared with intravenous administration, high-concentration protein formulations reduce administration volume and injection duration, improve patient compliance, save medical costs and resources, enable patient self-administration, and are compatible with convenient delivery routes including subcutaneous (SC) injection, emerging as a high-priority research direction in the biopharmaceutical industry in recent years.
Nevertheless, the physicochemical properties of antibody molecules are prone to alteration under high-concentration conditions, posing multiple challenges to formulation development. This article systematically elaborates on the core challenges in the development of high-concentration antibody formulations and summarizes scientifically validated early predictive strategies.
Core Challenges in High-Concentration Formulation Development
In high-concentration antibody solutions, intermolecular interactions readily induce reversible self-association of protein molecules. Compared with conventional low-concentration formulations, high-concentration counterparts are characterized by high viscosity, high density, pronounced coloration, turbidity and opalescence, poor colloidal stability, and elevated aggregation propensity, bringing substantial obstacles to stability control, manufacturing process scalability, and injectability of finished formulations.
1. Elevated Viscosity
The viscosity of high-concentration antibody solutions originates from complex intermolecular forces. These interactions effectively form transient large-scale networks of associated protein molecules that restrict fluid flow, thereby resulting in high solution viscosity. Key factors governing protein solution viscosity include excluded volume effects from steric hindrance, electrostatic repulsion between protein molecules, electrostatic attraction induced by charge-charge and charge-dipole interactions, as well as hydrophobic interactions between nonpolar and aromatic surfaces of proteins (Figure 2).
The acceptable viscosity threshold for subcutaneously administered high-concentration formulations is generally controlled below 20 cP. Excessively high viscosity not only causes injection difficulty and patient injection pain but also compromises filling accuracy, elevates production costs and technical complexity. Furthermore, high viscosity creates substantial bottlenecks in filtration and purification workflows and reduces overall manufacturing efficiency.
Based on the understanding of viscosity formation mechanisms, formulation optimization or excipient supplementation is commonly adopted to enhance protein stability and reduce solution viscosity. The most widely used viscosity-lowering excipients reported in literature and approved commercial products include salts (e.g., sodium chloride, L-arginine hydrochloride) and amino acids (e.g., arginine, proline, glycine) (Figure 3).
Arginine stands out as the most prevalent natural viscosity-reducing excipient; its mechanisms for lowering viscosity and maintaining stability of high-concentration formulations involve charge shielding, cation-π interactions, and hydrogen bonding. Sodium chloride reduces viscosity by modulating electrostatic repulsion among protein molecules. The effects of additives on protein intermolecular interactions vary significantly depending on the intrinsic properties of the target protein, excipient type, and dosage, requiring case-specific evaluation and optimization. Rational formulation and process optimization enables simultaneous viscosity reduction and preservation of drug stability.
2. Increased Aggregation Propensity
High-concentration formulations are susceptible to protein self-association, leading to aggregate formation. Enhanced intermolecular hydrophobic interactions facilitate the generation of subvisible and visible particles. Excipients such as sugars, salts, surfactants, and amino acids can mitigate aggregation risks by balancing intermolecular attractive and repulsive forces or modulating solution pH; lyophilization also serves as an effective mitigation strategy.
Sucrose and trehalose stabilize monoclonal antibodies by inducing protein hydration, preserving native folded conformation, reducing aggregation and denaturation in both liquid and lyophilized formulations, and acting as cryoprotectants to enhance long-term stability of frozen drug products. Salts contribute to the stabilization of protein structural integrity. Nonionic surfactants including Polysorbate 20/80 and Poloxamer 188 mitigate interfacial aggregation.
3. Diminished Physicochemical Stability
Under high-concentration conditions, drug molecules are more susceptible to physical and chemical degradation such as aggregation and fragmentation. As protein concentration increases, the levels of residual host cell proteins (HCPs) rise correspondingly, accompanied by elevated esterase concentrations. These esterases accelerate the degradation of surfactants such as polysorbates, impairing their capacity to stabilize protein molecules. In process development, optimization of process parameters and rational selection of excipients and additives can improve the long-term stability of high-concentration formulations.
4. Manufacturing Process Challenges
Driven by the clinical advantages of subcutaneous administration, the demand for high-concentration antibody therapeutics continues to rise, accompanied by a series of technical hurdles in manufacturing process development.
4.1 Drug Substance Manufacturing: Ultrafiltration/Diafiltration (UF/DF)
UF/DF processes are employed to concentrate the drug substance and perform buffer exchange to achieve target protein concentration, excipient composition, physiological osmolarity, ensuring administration safety, maintaining therapeutic efficacy, and extending shelf life. To maximize recovery yield, over-concentration is often required during buffer exchange and concentration of high-concentration protein formulations.
However, a slight incremental increase in protein concentration within a critical range may trigger a sharp surge in viscosity. Elevated viscosity leads to pressure buildup during UF/DF, limiting further concentration, restricting the maximum achievable protein concentration, and compromising recovery yield (Figure 4). Increased shear stress and interfacial effects also exacerbate protein aggregation risks and undermine product stability. Additionally, volume exclusion effects and Donnan effects are amplified at high concentrations, causing undesired drift in final excipient concentrations, solution pH, and buffer attributes.
Process optimization strategies include elevating processing temperature, adjusting pH, optimizing buffer systems to modulate electrostatic interactions, adopting kosmotropic salt systems, and selecting optimal membrane screen configurations to reduce pressure drop across the UF/DF module. Operationally, appropriately increasing buffer concentration compensates for dialysis buffer offset, and optimized rinsing protocols ensure post-recovery excipient concentrations meet target specifications.
4.2 Terminal Sterilization Filtration
Key challenges in sterile filtration of high-concentration proteins include low filtration flux, prolonged processing time, and increased product loss. Higher aggregation propensity exacerbates filter fouling, which impairs sterilization capacity. Classic membrane fouling mechanisms encompass pore constriction, pore blocking, and cake filtration. Moreover, larger filter areas introduce increased dead volume, further aggravating product loss of high-concentration materials.
From a process perspective, increasing filter area can improve flux but may elevate product loss; installation of pre-filters prior to sterile filtration effectively enhances final throughput. Since protein self-association is most pronounced at the isoelectric point (pI), performing sterile filtration away from the protein pI can optimize filtration performance. Formulation composition adjustment also improves filterability. In terms of membrane selection, highly hydrophilic filters mitigate hydrophobic fouling and protein aggregation.
4.3 Formulation Filling Process
High viscosity associated with high-concentration solutions creates multiple challenges in formulation filling production, including difficulties in bulk solution stirring and filtration, as well as dripping, line blockage, and poor filling accuracy during filling operations. Increased viscosity extends the cycle time of mixing and filtration processes, compromises filling volume accuracy, and substantially raises production costs.
Furthermore, high-viscosity drug solutions increase injection force, rendering drug aspiration and administration labor-intensive and compromising clinical usability. In manufacturing practice, rational selection of filling pipelines and needle dimensions is critical to avoid excessive flow resistance and ensure filling precision. Filling parameters including pump speed and anti-drip suck-back values should be adjusted and validated to achieve optimal performance. Simulated filling tests using viscosity-matched surrogate solutions prior to formal production guarantee filling accuracy specifications. Idle downtime during filling should be strictly controlled, as high-concentration high-viscosity protein solutions are prone to volatilization and crystallization.
4.4 Lyophilization Process
Elevated protein concentration impacts critical quality attributes (CQAs) of lyophilized protein drug products, including physical appearance, cake structure, viscosity, osmolarity, and reconstitution time, as well as lyophilization process parameters such as primary drying duration. The key bottlenecks for high-concentration lyophilized formulation development include low collapse temperature (Tc), unsatisfactory cake morphology, prolonged reconstitution time, and excessively high viscosity of reconstituted solutions (Figure 5).
Reconstitution time is governed by multiple intertwined factors including crystallinity, wettability, pore structure, and liquid permeability; moderate crystallinity, macroporous structure, and low reconstituted viscosity are core determinants of accelerated reconstitution.
Challenges in high-concentration lyophilized formulation development can be addressed via formulation and lyophilization process optimization. Adjustments to lyophilization parameters (annealing protocol, headspace pressure), formulation attributes (protein concentration, filling/reconstitution volume), container configuration, and reconstitution conditions (temperature, shaking frequency) modify the crystal morphology, pore structure, hydrophilicity, and mechanical strength of lyophilized cakes, thereby improving cake appearance and mitigating prolonged reconstitution issues.
Fundamental Development Strategies for High-Concentration Formulations
1. Feasibility Assessment and Early Prediction
Intrinsic protein stability is a prerequisite for successful high-concentration formulation development. Early-stage feasibility evaluation is indispensable for candidate molecules. For lead antibodies screened via high-throughput experimentation and computational simulation, stability characterization is performed to validate the accuracy of process and formulation stability prediction.
1.1 High-Throughput Screening-Based Prediction
High-throughput microscale experimentation enables efficient screening of optimal antibody candidates and base formulations, providing fundamental guidance for high-concentration antibody formulation development. Commonly employed analytical techniques include:
Dynamic Light Scattering (DLS): Rapid characterization of aggregate particle size and polydispersity to evaluate aggregation propensity;
Differential Scanning Calorimetry (DSC): Determination of thermal stability; higher Tm values indicate enhanced structural stability at high concentrations;
Rheometer/Viscometer: Measurement of viscosity across zero-shear and shear-thinning regimes, with correlation to temperature and shear rate; viscosity profiling over a concentration gradient predicts rheological behavior at ultra-high concentrations;
Analytical Ultracentrifugation and NMR: Auxiliary characterization of reversible protein aggregation and intermolecular interaction patterns.
Additionally, high-throughput excipient array screening rapidly evaluates the effects of different buffers, stabilizers, and solubilizers on antibody stability and viscosity.
1.2 Computational Simulation-Assisted Prediction
Artificial intelligence and computational modeling enable developability assessment at the molecular level. Homology modeling constructs 3D antibody structures to analyze surface hydrophobicity, charge distribution, and isoelectric point; molecules with reduced hydrophobic surface regions and uniform charge distribution exhibit lower aggregation tendency at high concentrations.
Molecular Dynamics (MD) simulation mimics intermolecular interaction intensity under high-concentration conditions to predict aggregation risk and viscosity trends. Computational simulation reduces experimental trial-and-error, provides directional guidance for laboratory screening, and significantly improves development efficiency.
2. Formulation Development
Excipients play essential roles in solubilization, stabilization, and viscosity reduction for high-concentration antibody formulations. Rational excipient addition modulates intermolecular antibody interactions to lower viscosity and enhance physicochemical stability. As summarized in Table 2, common excipients in FDA-approved high-concentration antibody formulations include buffers, sugar/polyol protectants, surfactants, amino acid stabilizers, viscosity reducers, antioxidants, and chelating agents.
Lyophilization is a well-established strategy to improve the long-term stability of high-concentration liquid formulations, offering benefits including enhanced stability, reduced storage and transportation costs, and flexible dosage adjustment. Therefore, high-concentration formulation development requires rational excipient selection and dosage form design, with comprehensive multi-dimensional evaluation to identify optimal formulations that maintain colloidal, physicochemical, and visual stability.
3. Novel Drug Delivery Strategies for High-Concentration Formulations
Subcutaneous delivery of high-concentration protein formulations has witnessed remarkable technological advances to overcome the limitations of conventional administration routes:
Aqueous-based microparticle suspension technology enables ultra-high concentration (>300 mg/ml) protein delivery with small injection volume and superior stability;
Recombinant human hyaluronidase (rHuPH20) enhances local tissue permeability to facilitate high-dose subcutaneous administration;
Spray drying combined with surfactant formulation supports ultra-high-concentration subcutaneous delivery;
Wearable on-body delivery systems (OBDS) enable continuous infusion of 3–100 mL drug solutions;
Emerging technologies including nanoparticle formulations for inhalation/injection, spray drying, spray freeze-drying, and protein particle crystallization provide innovative alternatives for subcutaneous delivery.
Conclusion
Rising clinical demand for high-concentration antibody therapeutics necessitates overcoming multifaceted challenges in stability control, viscosity modulation, process compatibility, and clinical safety balance. Rational excipient selection effectively reduces solution viscosity and enhances formulation stability. Early developability prediction integrating high-throughput screening and computational simulation enables upfront risk identification, optimizes antibody candidates and formulation designs, and substantially reduces late-stage development costs.
Practically, optimal development strategies require case-specific comprehensive evaluation based on intrinsic antibody properties and formulation requirements to generate potent, stable high-concentration protein products. In the future, continuous advancement in predictive analytics and manufacturing innovation will further elevate development efficiency and product quality of high-concentration formulations, delivering safer and more convenient therapeutic options for patients.
